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Clinical and immunologic outcome of patients with cartilage hair
hypoplasia after hematopoietic stem cell transplantation
Abstract
Cartilage-hair hypoplasia (CHH) is a rare autosomal recessive disease caused by mutations in the RMRP
gene. Beside dwarfism, CHH has a wide spectrum of clinical manifestations including variable grades of
combined immunodeficiency, autoimmune complications, and malignancies. Previous reports in single
CHH patients with significant immunodeficiencies have demonstrated that allogeneic hematopoietic
stem cell transplantation (HSCT) is an effective treatment for the severe immunodeficiency, while
growth failure remains unaffected. Because long-term experience in larger cohorts of CHH patients after
HSCT is currently unreported, we performed a European collaborative survey reporting on 16 patients
with CHH and immunodeficiency who underwent HSCT. Immune dysregulation, lymphoid malignancy,
and autoimmunity were important features in this cohort. Thirteen patients were transplanted in early
childhood ( approximately 2.5 years). The other 3 patients were transplanted at adolescent age. Of 16
patients, 10 (62.5%) were long-term survivors, with a median follow-up of 7 years. T-lymphocyte
numbers and function have normalized, and autoimmunity has resolved in all survivors. HSCT should
be considered in CHH patients with severe immunodeficiency/autoimmunity, before the development of
severe infections, major organ damage, or malignancy might jeopardize the outcome of HSCT and the
quality of life in these patients.
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Cartilage-hair hypoplasia (CHH) is a rare
autosomal recessive disease caused by
mutations in the RMRP gene. Beside
dwarfism, CHH has a wide spectrum of
clinical manifestations including variable
grades of combined immunodeficiency,
autoimmune complications, and malig-
nancies. Previous reports in single CHH
patients with significant immunodeficien-
cies have demonstrated that allogeneic
hematopoietic stem cell transplantation
(HSCT) is an effective treatment for the
severe immunodeficiency, while growth
failure remains unaffected. Because long-
term experience in larger cohorts of CHH
patients after HSCT is currently unre-
ported, we performed a European collabo-
rative survey reporting on 16 patients
with CHH and immunodeficiency who un-
derwent HSCT. Immune dysregulation,
lymphoid malignancy, and autoimmunity
were important features in this cohort.
Thirteen patients were transplanted in
early childhood ( 2.5 years). The other 3
patients were transplanted at adolescent
age. Of 16 patients, 10 (62.5%) were long-
term survivors, with a median follow-up
of 7 years. T-lymphocyte numbers and
function have normalized, and autoimmu-
nity has resolved in all survivors. HSCT
should be considered in CHH patients
with severe immunodeficiency/autoimmu-
nity, before the development of severe
infections, major organ damage, ormalig-
nancy might jeopardize the outcome of
HSCT and the quality of life in these
patients. (Blood. 2010;116(1):27-35)
Introduction
Cartilage-hair hypoplasia (CHH) is a rare form of autosomal
recessive dwarfism, first described in the Old Order Amish
population of Pennsylvania.1 CHH has a wide spectrum of clinical
characteristics including: prenatal onset of growth failure, metaphy-
seal chrondrodysplasia, fine and sparse hair, immunodeficiency,
anemia, Hirschsprung disease, orthopedic problems, and increased
risk of malignancies. Incidence is estimated at 1.5 in 1000 births in
the Amish and 1 in 23 000 in the Finnish population.2-5
CHH is caused by mutations of the RMRP gene, that maps on
chromosome 9p21-p12 and encodes for the RNA component of the
mitochondrial RNA processing (MRP) endoribonuclease. This
RNA-cleaving enzyme encodes for structural RNAand plays a role
in nuclear DNA replication and cell growth. Recent data indicate
that RMRP forms a ribonucleoprotein complex with the telomerase
reverse transcriptase (TERT) catalytic subunit. This complex has
RNA polymerase activity and produces dsRNAs that can be
processed to small-interfering RNAs in a Dicer-dependent man-
ner.6 In CHH patients, mutations of this gene have been shown to
interfere with the expression of RMRP transcript and may affect a
variety of biologic processes.7-14
The immunodeficiency in patients with CHH is very variable,
but more than 30% have significant CD4 and CD8 lymphocyto-
penia. Normal in vitro lymphocyte proliferation upon stimulation
with mitogens is seen in less than 20% of patients. Humoral
immunity may also be affected, with deficiencies in immunoglobu-
lin A (IgA) and immunoglobulin G (IgG) subclasses being most
common.15,16 Defective immunity plays an important role in the
morbidity and mortality of these patients. Ma¨kitie et al17-19 reported
a 21-fold increased risk of mortality in CHH patients, mostly as a
result of infections, especially in younger patients. There is also an
increased risk of malignancies, particularly non-Hodgkin lym-
phoma and basal cell carcinoma. The prognosis of these patients
after development of malignancies is poor.18 Long-term impair-
ment of regulatory and cytotoxic T-lymphocyte immunity may
explain the prevalence of Epstein-Barr virus (EBV)–associated
malignant lymphomas and immune dysregulation causing autoim-
mune diseases in CHH patients.20,21 Kavadas et al22 showed that
RMRP mutations are responsible for a variable spectrum of
immunodeficiencies and should be considered even in patients
without skeletal dysplasias.
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Hematopoietic stem cell transplantation (HSCT) has pro-
foundly changed the natural history of severe T-lymphocyte
deficiencies by curing many patients with severe combined immu-
nodeficiency (SCID).23,24 Patients with more moderate T-lympho-
cyte dysfunction (eg, CD40L deficiency) or with phagocyte
disorders (eg, chronic granulomatous disease) were also shown to
have excellent outcome rates after HSCT, whereas only rarely did
they reach the age of 30 with best conventional treatment.25-27
Hence, there is great hope that HSCT-associated restoration of
normal T-lymphocyte and natural killer (NK)–cell immunity in
CHH patients may also prevent lymphoid malignancy, comparable
with patients with Wiskott-Aldrich syndrome, X-linked lymphopro-
liferative disease, Nijmegen breakage syndrome, Immunodeficiency-
Centromeric instability–Facial anomalies syndrome or Dyskera-
tosis congenita after successful HSCT.28-34 In addition, HSCT
should effectively prevent immune dysregulation and autoimmu-
nity as shown previously in other immunodeficiencies and rheu-
matic diseases.35
Previous single case reports have demonstrated that allogeneic
HSCT is able to correct the combined immunodeficiency in CHH
patients; however, long-term outcome after HSCT are lacking and
particularly the outcome of autoimmune disease in larger cohorts of
CHH patients remains unknown.36-38 In this European collaborative
survey, we describe the largest cohort of CHH patients (n 16)
who underwent allogeneic HSCT with a minimum follow-up of
1 year, and analyze the characteristics, complications, and the
long-term outcome of this procedure.
Methods
Data collection
All members of the Inborn Errors Working Party of the European Bone
Marrow Transplantation (EBMT) group were contacted, and data were
retrospectively collected from 9 European institutions with 16 CHH
patients treated with allogeneic HSCT between 1991 and 2006. All
participating institutions approved this retrospective study. Indication for
HSCT, age, donor type, conditioning regimen, immune-reconstitution,
post-HSCT complications (including graft-versus-host disease [GVHD]
and growth, orthopedic, and lung problems), and outcomes were reviewed
from medical records. Data analysis was performed in October 2009.
Lymphocyte subsets analysis
Lymphocyte markers were measured as previously described. Briefly, blood
was incubated with CD3, CD4, CD8, CD19, and CD56 monoclonal
antibodies (Beckman Coulter), erythrocytes were lysed, and cells sus-
pended in a solution with phosphate-buffered saline/bovine serum albumin
and sodium azide. Results were analyzed with the Cytomics FC 500
(Beckman Coulter).
Lymphocyte function analysis
T-lymphocyte proliferation was evaluated in vitro after exposure to
phytohemagglutinin, Concanavalin A, and pokeweed. After 72 hours,
T-lymphocyte proliferative activity was determined by measuring the
incorporation of tritiated thymidine into newly synthesized DNA.
Statistical analysis
The Wilcoxon signed ranks test (SPSS 17) was used to compare the number
of lymphocyte subpopulations before and after HSCT. A P value of .05 or
less was considered to be significant.
Clinical and immunologic characteristics
Patient characteristics are shown in Table 1. Diagnosis of CHH was established
on classical clinical features in all but 2 patients. In these 2 patients, the diagnosis
was done on genetic basis because they were very young and had no charac-
teristics of skeletal dysplasia. Mutations in RMRP were found in 12 patients of
whom 9 were compound heterozygotes.
All patients had combined immunodeficiency with or without autoim-
mune features before HSCT. Immunodeficiency was the main indication for
HSCT. Two patients underwent transplantation after the development of
EBV-related non-Hodgkin lymphoma associated with central nervous
system compromise (patient 14 [pt 14]) and relapsed non-Hodgkin lym-
phoma and CMV-induced bone marrow failure (pt 16). Pre-existing
autoimmunity and inflammatory skin lesions were a prominent feature in 5
of 16 patients (patient nos. 3, 5, 8, 11, and 12; Table 1). Thirteen patients
were transplanted in early childhood (mean age 2.5 years). Three patients
underwent transplantation in adolescent age (pt 14, pt 15, and pt 16).
Pretransplantation immunologic abnormalities are summarized in Table
2. A striking abnormality was lymphopenia with impaired T-lymphocyte
immunity (median lymphocyte count 1043 cells/L, range 267-2030).
Patient values in comparison with normal median numbers for age are
shown in Table 3. T-lymphocyte subsets were more affected than B
lymphocytes and NK cells. The median CD3-cell number was 295 cells/L
(range 50-1400). The CD4-cell counts had a median of 189/L (range
40-960) while the median of CD8 cells was 95/L (range 4-568).
Mitogen-induced lymphocyte proliferation test values ranged from very
low to absent in all but 1 patient (pt 1).
The B-lymphocyte count was low in 2 patients (pt 2 and pt 11); the data
of 1 patient (pt 11) are not available because he received Rituximab before
the evaluation. Serum IgG, IgM, and IgA levels were rather variable. Levels
were normal in 7 patients, and in 2, all fractions were reduced. A combina-
tion of IgM and IgA low levels was seen in 2 patients. Isolated IgG
deficiency was present in 1 patient and combined IgG and IgA deficiency
was observed in 1 patient. Isolated IgA deficiency was detected in
2 patients. Pt 11 was under immunoglobulin substitution after Rituximab
administration.
Transplantation procedures
All patients were nursed in high-efficiency particulate absorbing filtered
rooms or in an isolator and received prophylaxis with intravenous
immunoglobulins and trimethoprim/sulfamethoxazole against Pneumocys-
tis jirovecii infection.
Thirteen patients received myeloablative conditioning with busulfan
(16-20 mg/kg in 4 divided doses) and cyclophosphamide (120-200 mg/kg).
Two patients received fludarabine-based reduced-intensity conditioning
and 1 patient received treosulfan-based conditioning. Cyclosporine A and a
short course of methotrexate were most frequently used for GVHD
prophylaxis. Anti–T-lymphocyte globulin or alemtuzumab was used in
matched unrelated donors (MUDs) and 2 haploidentical HSCTs, and
1 patient received OKT3 (Table 1).
Informed consent was given before HSCT in accordance with the
Declaration of Helsinki.
Results
Five patients underwent HSCT with HLA-identical siblings, 8 had
MUDs, and 3 had haploidentical donors. A total of 13 of 14 patients
who received myeloablative conditioning, and 2 of 3 who received
reduced-intensity conditioning engrafted. Both types of condition-
ing regimen were well tolerated. No severe hepatic veno-occlusive
disease occurred. There was no grade 3/4 GVHD.
A total of 6 of 16 patients (37%) died, of whom 3 patients had
received extensive lymphocyte-depleted grafts from haploidentical
donors, 2 patients with matched unrelated, and 1 patient after
matched sibling transplantation. A total of 4 patients died during
the first year after HSCT, one due to disseminated adenovirus
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infection in myeloid aplasia, the other 3 patients due to infectious
complications despite full donor chimerism The survival rate for
the matched sibling and unrelated donor transplantation was 10/13
(80%; Table 1).
There were 2 late deaths observed, both with incomplete
immune reconstitution; 1 patient with pneumococcal sepsis 2.5 years
post-HSCT, and 1 patient 4 years post-HSCT with cytomegalovirus
(CMV) infection and severe autoimmune thrombocytopenia lead-
ing to lethal cerebral hemorrhage.
During and after HSCT, viral and fungal infectious were major
problems and occurred in 8 patients (50%). Two patients died from
disseminated adenovirus disease. Two patients had Polyoma BK
viral infections, one with blood viremia and one with hemorrhagic
cystitis only. One patient each had CMV disease with pneumonitis,
EBV-associated lymphoproliferative disease, and human herpes
virus type 6 viremia. Invasive fungal infections were seen in
2 patients, one with lung aspergillosis and one with a multifungal
infection of the lung, with Candida and Aspergillus species
followed by untreatable sinocerebral mucormycosis, which was
lethal at 10 months after transplantation despite full donor
chimerism.
Characteristics of patients with long-term follow-up
The 10 survivors are well and have normal immunity The median
follow-up in the 10 long-term survivors was 7 years (range
1.6-16 years).
Immunologic characteristics after HSCT
The major impact of the HSCT was seen in the improvement of the
number and function of the lymphocytes (Table 3; Figure 1). The
median CD3-lymphocyte count at last follow-up was 1552/L
(P  .006, Wilcoxon signed rank test). The median CD4-
lymphocyte count was 857/L (P  .01, Wilcoxon signed rank
test), and the median CD8-lymphocyte count was 652/L (P .003,
Wilcoxon signed rank test).
The lymphocyte proliferation to antigen stimulation normalized
or improved in all patients. The response to specific antigens was
normal in all long-term survivors.
The improvement in the B-lymphocyte and NK-cell counts was
not statistically significant. Four patients showed a remaining
isolated IgA deficiency (pt 2, pt 12, and pt 14), and 1 patient with no
successful donor immune reconstitution needed continued intrave-
nous immunoglobulin substitution until death 4 years post-HSCT.
Characteristics of the donor chimerism
Donor chimerism was assessed in 12 patients, and was measured
in whole blood in some centers and as lineage-specific chimer-
ism in other centers. In patients in whom whole blood chimerism
was performed, donor chimerism was 100%; in those patients
with cell line–specific chimerism, CD3 chimerism was 90%
donor or more and myeloid cell-lineage donor chimerism was
70% or more (Table 1).
A total of 7 patients had pre-existing moderate bronchiectasis
before HSCT. After HSCT, lung function stabilized or improved
and pre-existing bronchiectasis did not progress. HSCT had no
major impact on the growth and development of these patients
(Figure 2). All but 2 patients, who were below fifth percentile
before HSCT, reached the expected CHH-length percentile for age
(see also growth curves39). One patient (pt 13) had persisting
growth hormone deficiency after HSCT, and growth hormone was
recently substituted. Patients with CHH and recurrent lung infec-
tion are known to have less growth potential than other CHH
patients. It is remarkable, therefore, that the majority of our patients
achieved catch-up growth for the disease after HSCT, probably
because immunologic improvement led to a reduction in the
frequency of lung infection (growth curves). The intellectual
development is normal in all patients. None have developed
malignancy or de novo autoimmune disease to date.
Discussion
The first report of a patient with CHH who underwent HSCT
showed a clear benefit in terms of restoring impaired immunity, but
no improvement of the associated skeletal problems.36,37 Guggen-
heim et al38 also demonstrated that HSCT provides prolonged
engraftment and stable immune reconstitution in 3 patients with
CHH and combined immunodeficiency.
We describe the largest so far reported cohort of patients with
CHH who underwent HSCT. The patients were characterized by
T-lymphocyte immunodeficiency of various degrees, contributing
to infectious complications, autoimmune disorders, and lymphoid
malignancies. In addition, 2 patients presented with clinical
characteristics of Omenn syndrome.
The overall survival rate was 10/16 (63%) and 10/13 (80%) for
the patients receiving matched sibling transplants or unrelated
donor transplants. These results are in keeping with the European
results for other T-cell immune deficiency, and highlight the poor
Table 3. Lymphocyte populations and function in survivors and immunoglobulin levels at last follow-up after HSCT
Pt 1 Pt 3 Pt 5 Pt 7 Pt 9 Pt 10 Pt 12 Pt 13 Pt 14 Pt 15
Age, y 11 8 17 7 4 15 11 10 14 17
Lymphocytes/L 1130 2520 3757 2662 2758 4410 1070 2600 2250 2200
CD3/L 654 1714 2454 2336 1933 2293 817 1700 1552 1514
CD4/L 386 857 1554 979 1130 794 551 1080 900 264
CD8/L 268 857 900 1357 803 1323 266 620 652 1250
C19/L 164 529 500 226 473 573 65 520 495 285
NK cells/L 175 n.a. 300 119 291 1411 95 180 67 330
IgG Normal Normal Normal Normal Normal Normal Normal Normal
(Low IgG2)
Normal Normal
IgM Normal Normal Normal Normal Normal Normal Normal Normal Normal Normal
IgA Normal Absent Normal Low Normal Normal Absent Absent Absent Normal
Response to mitogens Normal Normal Improved Normal Normal Normal Improved Improved Improved Improved
Pt indicates patient; and n.a., not available.
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results from haploidentical HSCT, but encouraging results when
well-matched donors are used.
Conditioning regimens with busulfan and cyclophosphamide
were effective and well tolerated. Fludarabine-based reduced-
intensity conditioning regimens were used more recently, in
particularly in patients who already have significant organ damage
with higher risk for transplant-related mortality. The limited
number of patients treated by reduced-intensity conditioning in this
series does not permit a draw to conclusions on the efficacy of this
approach in CHH.
Early work of Pierce and Polmar40,41 clearly showed that there
was an intrinsic defect in the proliferative capacity of RMRP-
deficient lymphocytes, which was confirmed by work of Kooijman
et al.42 Exactly how the RMRP mutations affect the cell-cycle is not
fully understood, but data strongly suggest that there is a partial cell
defect in the transition from G0 to the G1 phase and/or defects in the
progression through the G1 phase. This could explain at least in part
the severe lymphocytopenia in some patients with CHH and the
observed low lymphocyte proliferation to specific mitogens in
vitro. In addition, the recent demonstration that RMRP forms a
complex with TERT provides strong evidence to a role of RMRP in
prevention of cellular senescence and maintenance of telomere
homeostasis.6
Reduced thymic output of patients with CHH and combined
immunodeficiency, measured by T-lymphocyte receptor excision circles,
has been demonstrated.22 Furthermore, it has been recently shown that
thymic abnormalities in these patients also include reduced expression
of aire (a transcription factor involved in clonal deletion of self-reactive
T cells) and poor generation of thymic natural regulatory T cells.43 These
abnormalities are likely involved in the autoimmune manifestations of
CHH. Autoimmunity is well described in other immunodeficiencies
with impaired thymic output including partial DiGeorge syndrome and
Omenn syndrome.44 Autoimmunity, mostly hematologic, has been
described in patients with CHH and was common in our cohort. It is
possible that the frequency of autoimmunity has been underestimated in
patients with CHH and should be actively sought for.44-46 The immune
dysregulation was successfully corrected in all but 1 patient who had
impaired immune reconstitution (pt 13) in whom severe autoimmune
thrombocytopenia led to cerebral hemorrhage and death. Inflammatory
skin lesions were also normalized post-HSCT.
Bone marrow hypoplasia, often transient, has been described in
patients with CHH. In our group of patients, 5 of 16 patients developed
various degrees of bone marrow failure. The etiology of this complica-
tion could be related to RMRP-associated cell-cycle regulation, but viral
infections should also be a factor. In all such cases, this HSCT
successfully restored bone marrow function and cellularity.
Transplantation-related mortality in our cohort was mostly a result of
infectious complications. Two late deaths were seen, with 1 death at
2.5 years post-HSCT because of pneumococcus sepsis and 1 death at
4 years from severe autoimmune thrombocytopenia associated with
Figure 1. Lymphocyte counts by patient related to
age before and after HSCT. Top left panel shows CD3
cells per L before HSCT, and top right after HSCT.
Middle left panel shows CD4 per L before HSCT, and
middle right after HSCT. Bottom left panel shows CD8 per
L before HSCT, and bottom right after HSCT.
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CMV lung disease. Long-term follow-up with careful assessment of T-
and B-lymphocyte function is therefore necessary.
After successful HSCT, there was a significant increase of
the T-lymphocyte numbers, with only minor changes of B
lymphocyte and NK–cell numbers. Donor chimerism remains
stable and the lymphocyte function was improved in all patients.
All survivors attend normal schools and have a good quality of
life.
Patients with RMRP mutations showed a striking variability in
clinical manifestation even within sibships, with no genotype/
phenotype correlation,17 contributing to the challenge in selecting
those patients who will benefit from HSCT, while not selecting
those who do not require the procedure. With our current understand-
ing, not all CHH patients should be considered for HSCT but only
those with chronic or recurrent infection in association with
autoimmunity or bone marrow hypoplasia if a well-matched donor
is available. Patients with CHH should have careful assessment of
lymphocyte numbers and function, but those with normal results
should be considered for HSCT in the event of evolving infections,
autoimmunity and/or blood cytopenias, before development of
significant organ damage or malignancy. It is questionable whether
haploidentical HSCT should be considered in this setting. In the
case of lacking compatible unrelated donor, unrelated cord blood
transplantations should be investigated as a true alternative for
haploidentical transplantations. This could have a major impact on
the survival and quality of life of young CHH patients. In the
meantime, cohort studies with genotype-phenotype correlations are
urgently needed to address the question that patients will benefit
most from the procedure.
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